This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Sancuso-product-image

SANCUSO®

SANCUSO transdermal patch is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic multi-day chemotherapy in adult patients with swallowing difficulties.1

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Click here for prescribing information.

Tolerability

Like all medicines, SANCUSO can cause side effects, although not everybody gets them.

The most commonly reported adverse reaction in clinical studies was constipation, occurring in approximately 8.7% of patients.1 Application site irritation is uncommon and may affect up to 1 in 100 people.1

Post marketing authorisation surveillance has shown application site reactions of pain, pruritus, erythema, rash, and irritation, with a frequency of not known.

Adverse reactions from clinical studies and spontaneous reports with SANCUSO are listed in the table below.

Within the system organ class, the adverse reactions are listed by frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).1

Adverse reactions are presented in order of decreasing seriousness within each frequency grouping.

Description of selected adverse reactions

Patients who are being treated with moderately or highly emetogenic chemotherapy may still experience vomiting despite treatment with antiemetic therapy, including SANCUSO.1

Class effects1

Class effects for granisetron seen with other formulations (oral and intravenous) include the following:

  • Hypersensitivity reactions, e.g. anaphylaxis, urticaria.
  • Insomnia.
  • Headache.
  • Extrapyramidal reactions.
  • Somnolence.
  • Dizziness.
  • QT prolongation.
  • Constipation.
  • Diarrhoea.
  • Elevated hepatic transaminases.
  • Rash.
  • Asthenia.

Average:

  • References

    1. SANCUSO 3.1 mg/24 hours transdermal patch SPC.

    KKI/UK/IM-M1/0001 November 2023